| Recruiting | A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer NCT07450976 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 2 |
| Recruiting | A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ART NCT07221253 | AstraZeneca | Phase 3 |
| Recruiting | Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer NCT07146646 | Case Comprehensive Cancer Center | Phase 2 |
| Recruiting | Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients NCT06529718 | UNICANCER | Phase 2 |
| Recruiting | Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC NCT07142226 | CHA University | — |
| Recruiting | ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer NCT07151118 | CHA University | — |
| Not Yet Recruiting | Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer NCT07159217 | Peking Union Medical College Hospital | Phase 2 |
| Completed | A Study to Evaluate the Association of Biliary Complications and Treatment Duration in Unresectable BTC Patien NCT07101874 | AstraZeneca | — |
| Recruiting | A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy f NCT07135544 | Yongjun Chen | Phase 2 |
| Recruiting | Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors NCT07021066 | SystImmune Inc. | Phase 1 |
| Recruiting | Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresect NCT07506057 | Xiujuan Qu | Phase 2 |
| Recruiting | A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fi NCT06793709 | Eisai Co., Ltd. | — |
| Completed | ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors NCT06973161 | AstraZeneca | — |
| Not Yet Recruiting | Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer NCT07003815 | Tongji Hospital | Phase 2 |
| Recruiting | Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer NCT07025174 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Not Yet Recruiting | Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malig NCT06993025 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer NCT07267078 | Peking Union Medical College Hospital | Phase 2 |
| Recruiting | A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer NCT06938321 | Akeso | Phase 1 / Phase 2 |
| Recruiting | Study for AZD4360 in Participants With Advanced Solid Tumours NCT06921928 | AstraZeneca | Phase 1 / Phase 2 |
| Recruiting | A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521 | Tanabe Pharma America, Inc. | Phase 1 / Phase 2 |
| Recruiting | The Study of Association of Helicobacter Infections in Biliary Tract Cancers NCT06909188 | Institute of Liver and Biliary Sciences, India | — |
| Recruiting | Ligufalimab and Cadonilimab in Advanced Liver Cancers NCT06789848 | University of Texas Southwestern Medical Center | Phase 2 |
| Recruiting | Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery NCT06731998 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | N/A |
| Recruiting | HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours NCT06708663 | Hangzhou Hanx Biopharmaceuticals, Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Phase 1 Study of LNCB74 in Advanced Solid Tumors NCT06774963 | NextCure, Inc. | Phase 1 |
| Not Yet Recruiting | A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemothera NCT06654947 | Fujian Cancer Hospital | Phase 2 |
| Recruiting | CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors NCT06937567 | Zhejiang University | EARLY_Phase 1 |
| Withdrawn | Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma NCT06017297 | Georgetown University | Phase 2 |
| Not Yet Recruiting | Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatmen NCT06662877 | Sun Yat-sen University | Phase 2 / Phase 3 |
| Recruiting | A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract NCT06620848 | Shanghai Zhongshan Hospital | Phase 2 |
| Recruiting | Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Biliary Tract Cancer Recurrence Surveillance NCT06653127 | Tongji Hospital | — |
| Active Not Recruiting | Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers (TOG/GI-SAFRADJU-2501) NCT06975917 | Ankara University | — |
| Recruiting | Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Trac NCT06546969 | University of Maryland, Baltimore | Phase 1 |
| Active Not Recruiting | AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer NCT06591520 | Akeso | Phase 3 |
| Recruiting | Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizuma NCT06648057 | CHA University | — |
| Recruiting | Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer NCT06467357 | AstraZeneca | Phase 3 |
| Not Yet Recruiting | Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumo NCT06531291 | RenJi Hospital | Phase 2 |
| Recruiting | Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC NCT05733598 | Replimune, Inc. | Phase 2 |
| Recruiting | A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer NCT06431490 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced NCT06282575 | Jazz Pharmaceuticals | Phase 3 |
| Not Yet Recruiting | Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract NCT06502080 | Shanghai Zhongshan Hospital | Phase 2 |
| Recruiting | Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in NCT06465563 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 2 |
| Recruiting | A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) NCT06428409 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Withdrawn | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures NCT06084689 | Institut Bergonié | Phase 2 |
| Recruiting | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors NCT06239194 | ModeX Therapeutics, An OPKO Health Company | Phase 1 / Phase 2 |
| Active Not Recruiting | Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC NCT06490107 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatmen NCT06451497 | Zumutor Biologics Inc. | Phase 1 |
| Recruiting | An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies NCT07282262 | Peking Union Medical College Hospital | Phase 2 |
| Not Yet Recruiting | HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract NCT06389500 | Harbin Medical University | Phase 2 |
| Active Not Recruiting | Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliar NCT06178445 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Recruiting | Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC NCT06320301 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Unknown | Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer NCT06255262 | China Medical University, China | Phase 1 / Phase 2 |
| Recruiting | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors NCT06293898 | SystImmune Inc. | Phase 1 |
| Completed | Frailty Scales for Predicting Chemotherapy Toxicity in Older Adults With Gastrointestinal Cancers NCT07184047 | Ankara Etlik City Hospital | — |
| Recruiting | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 NCT06219941 | AstraZeneca | Phase 2 |
| Active Not Recruiting | Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) NCT06109779 | AstraZeneca | Phase 3 |
| Unknown | Circulating Tumor DNA Guided Adjuvant Chemotherapy for Biliary Tract Carcinoma NCT06171321 | Shanghai East Hospital | N/A |
| Recruiting | CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in NCT06037980 | Gruppo Oncologico del Nord-Ovest | Phase 2 / Phase 3 |
| Recruiting | Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers NCT06139042 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Recruiting | Use of Ctdna in Patients With Gastrointestinal Tract Tumors NCT06202131 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Terminated | GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer NCT05998447 | Genome & Company | Phase 2 |
| Active Not Recruiting | Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) NCT05771480 | AstraZeneca | Phase 3 |
| Active Not Recruiting | Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure NCT05994001 | Shanghai Zhongshan Hospital | Phase 1 / Phase 2 |
| Recruiting | XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. NCT06792435 | Evopoint Biosciences Inc. | Phase 1 / Phase 2 |
| Recruiting | Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer NCT07062263 | Tata Memorial Centre | Phase 3 |
| Recruiting | Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatop NCT05451043 | AHS Cancer Control Alberta | Phase 2 |
| Completed | Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI NCT05835778 | AstraZeneca | — |
| Recruiting | Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With NCT05775159 | AstraZeneca | Phase 2 |
| Active Not Recruiting | Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers NCT05220046 | University of Nebraska | Phase 1 |
| Unknown | Impact of a European Training Program for Robotic Liver Surgery (LIVEROBOT) NCT05723705 | Amsterdam UMC, location VUmc | — |
| Recruiting | Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors NCT05784688 | TiumBio Co., Ltd. | Phase 1 / Phase 2 |
| Withdrawn | A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies NCT03999658 | Sorrento Therapeutics, Inc. | Phase 2 |
| Active Not Recruiting | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or NCT05506943 | Compass Therapeutics | Phase 2 / Phase 3 |
| Recruiting | MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer NCT07156058 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | N/A |
| Completed | Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, P NCT05512377 | Boehringer Ingelheim | Phase 2 |
| Recruiting | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tu NCT05489211 | AstraZeneca | Phase 2 |
| Unknown | Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carci NCT05509478 | The First Hospital of Jilin University | Phase 2 |
| Unknown | RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2 NCT05417230 | Jiangsu Cancer Institute & Hospital | Phase 2 |
| Unknown | The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies NCT05487443 | First People's Hospital of Hangzhou | Phase 2 / Phase 3 |
| Completed | New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION)- a Permanent Platfor NCT04896931 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | — |
| Recruiting | Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract C NCT05429697 | SMT bio Co., Ltd. | Phase 2 / Phase 3 |
| Recruiting | Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL S NCT04935853 | GERCOR - Multidisciplinary Oncology Cooperative Group | — |
| Completed | Blood Flow Restriction Exercise in Patients With Pancreatic, Biliary Tract, and Liver Cancer (PREV-Ex) NCT05044065 | Karolinska Institutet | N/A |
| Unknown | ctDNA Detection of MRD in Predicting Postoperative Recurrence in Biliary Tract Cancers：A Multicenter Prospecti NCT05743959 | The First Affiliated Hospital with Nanjing Medical University | — |
| Completed | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients NCT05253053 | TransThera Sciences (Nanjing), Inc. | Phase 1 / Phase 2 |
| Unknown | An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC NCT05327582 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | XmAb20717 in Advanced Biliary Tract Cancers NCT05297903 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Recruiting | Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemoth NCT05222971 | Asan Medical Center | Phase 2 |
| Recruiting | Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Trac NCT05065957 | InnoPharmax Inc. | Phase 2 / Phase 3 |
| Unknown | AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary Tract Cancer (ASCEND-BTC) NCT05667350 | Eastern Hepatobiliary Surgery Hospital | — |
| Completed | Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With NCT05254847 | Fudan University | Phase 2 |
| Terminated | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresect NCT04683939 | BioNTech SE | Phase 1 / Phase 2 |
| Unknown | Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Local NCT05156788 | Shanghai Zhongshan Hospital | Phase 2 |
| Unknown | Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy NCT06074029 | Peking Union Medical College Hospital | Phase 1 / Phase 2 |
| Terminated | Milademetan in Advanced/Metastatic Solid Tumors NCT05012397 | Rain Oncology Inc | Phase 2 |
| Completed | Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer NCT05052099 | University Hospital, Essen | Phase 1 / Phase 2 |
| Recruiting | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes NCT04907643 | Cedars-Sinai Medical Center | N/A |
| Completed | A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid NCT05116891 | Cantargia AB | Phase 1 / Phase 2 |
| Unknown | A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tra NCT05056116 | The Affiliated Hospital of Xuzhou Medical University | N/A |
| Unknown | Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Canc NCT03110484 | Samsung Medical Center | Phase 2 |
| Terminated | Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer NCT04727541 | AIO-Studien-gGmbH | Phase 2 |
| Terminated | A Study of HA121-28 Tablets in Advanced Biliary Tract Cancer NCT04784520 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 |
| Recruiting | AB122 Platform Study NCT04999761 | Taiho Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Observational Monocentric Study on Biliary Tract Cancer (BABEL) NCT05942807 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Completed | Biomarker Discovery in Patients With Advanced Biliary Tract Cancer NCT04871321 | CHA University | — |
| Terminated | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab NCT04779151 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Unknown | Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer NCT04401709 | Samsung Medical Center | Phase 3 |
| Completed | A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients NCT04677504 | Hoffmann-La Roche | Phase 2 |
| Active Not Recruiting | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors NCT04660929 | Carisma Therapeutics Inc | Phase 1 |
| Unknown | A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer NCT04608786 | Lee's Pharmaceutical Limited | Phase 1 |
| Completed | Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer. NCT04720131 | Beijing Friendship Hospital | Phase 2 |
| Withdrawn | A Trial of SHR1258 in Patients With Biliary Tract Cancer NCT04571710 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Unknown | Hepatobiliary Tumors Tissue Samples Acquisition NCT04445532 | Peking Union Medical College Hospital | — |
| Unknown | CIRcular and Non-coding RNAs as Clinically USeful Biomarkers in Pancreaticobiliary Cancers NCT04584996 | Royal Surrey County Hospital NHS Foundation Trust | — |
| Unknown | A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer NCT04329429 | RemeGen Co., Ltd. | Phase 2 |
| Completed | A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonis NCT04338685 | Hoffmann-La Roche | Phase 1 |
| Unknown | A Questionnaire Survey for Biliary Tract Cancers NCT04731220 | Kyungpook National University Chilgok Hospital | — |
| Terminated | Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer NCT04561453 | University of Washington | — |
| Terminated | Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectabl NCT04203160 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Unknown | Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlan NCT04333927 | Sun Yat-sen University | Phase 2 |
| Recruiting | Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequ NCT05520788 | Tongji Hospital | — |
| Unknown | PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors NCT05357196 | SciClone Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | Molecular Profiling of Advanced Biliary Tract Cancers NCT04318834 | McGill University Health Centre/Research Institute of the McGill University Health Centre | N/A |
| Withdrawn | A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer NCT04186156 | Karus Therapeutics Limited | Phase 2 |
| Unknown | Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional NCT04907864 | Kil Yeon Lee | Phase 2 |
| Completed | Effect of PVE on Surgical Outcomes and Long-term Survival in Perihilar Cholangiocarcinoma NCT06222619 | Seoul National University Hospital | — |
| Completed | Pembrolizumab in Biliary Tract Cancer NCT03260712 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Withdrawn | Molecular Profiling of Advanced Biliary Tract Cancers NCT03419247 | University Health Network, Toronto | N/A |
| Unknown | Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tra NCT04300959 | Zhejiang Cancer Hospital | Phase 2 |
| Terminated | Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer NCT04163900 | NuCana plc | Phase 3 |
| Unknown | COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable Biliary Tract Cancer NCT03898895 | Sun Yat-sen University | Phase 2 |
| Completed | Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer NCT03937895 | SMT bio Co., Ltd. | Phase 1 / Phase 2 |
| Withdrawn | Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer NCT03818997 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Terminated | Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Ca NCT04057365 | Massachusetts General Hospital | Phase 2 |
| Terminated | Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC NCT04066491 | EMD Serono Research & Development Institute, Inc. | Phase 2 / Phase 3 |
| Withdrawn | FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabi NCT03110510 | Samsung Medical Center | Phase 2 |
| Unknown | A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in NCT04692051 | Huazhong University of Science and Technology | Phase 2 |
| Completed | Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate NCT03673072 | Krankenhaus Nordwest | Phase 3 |
| Terminated | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumor NCT04234113 | SOTIO Biotech AG | Phase 1 |
| Completed | Trastuzumab in HER2-positive Biliary Tract Cancer NCT03613168 | Changhoon Yoo | Phase 2 |
| Completed | Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary T NCT03785873 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Completed | Predicting Disease Progression and/or Recurrence in Cancer NCT04776837 | Massachusetts General Hospital | — |
| Active Not Recruiting | Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy NCT03631173 | Oslo University Hospital | N/A |
| Unknown | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients NCT03924466 | Universitair Ziekenhuis Brussel | Phase 2 |
| Completed | Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following NCT03639935 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma NCT03833661 | EMD Serono Research & Development Institute, Inc. | Phase 2 |
| Completed | FOLFIRINOX for 2nd-line Treatment of BTC NCT03778593 | Dong-A University Hospital | Phase 2 |
| Recruiting | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers NCT03801083 | Udai Kammula | Phase 2 |
| Completed | A Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in Advanced Biliary Tract Cancer NCT03796429 | Shanghai Zhongshan Hospital | Phase 2 |
| Completed | Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer NCT04642664 | Peking Union Medical College Hospital | Phase 2 |
| Unknown | Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome Sequencing NCT03718897 | Ji Kon Ryu | — |
| Completed | Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subj NCT03531320 | InnoPharmax Inc. | Phase 1 / Phase 2 |
| Unknown | A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients NCT03873532 | Hutchison Medipharma Limited | Phase 2 / Phase 3 |
| Active Not Recruiting | A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors NCT03695952 | Asan Medical Center | — |
| Unknown | Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos NCT03668418 | University of Pisa | — |
| Recruiting | Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Can NCT03482102 | Massachusetts General Hospital | Phase 2 |
| Unknown | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors NCT03475953 | Institut Bergonié | Phase 1 / Phase 2 |
| Completed | Patient Activation Through Counseling, Exercise and Mobilization NCT03411200 | Herlev and Gentofte Hospital | N/A |
| Active Not Recruiting | A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer NCT03440450 | Fujifilm Pharmaceuticals U.S.A., Inc. | Phase 1 |
| Completed | SHR-1210 in Combination With GEMOX in Patients With Advanced BTC NCT03486678 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Completed | Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least O NCT03110328 | Samsung Medical Center | Phase 2 |
| Completed | Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Canc NCT03044587 | AIO-Studien-gGmbH | Phase 2 |
| Completed | Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer NCT04656249 | Peking Union Medical College Hospital | Phase 2 |
| Completed | Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer NCT03231176 | ASLAN Pharmaceuticals | Phase 2 |
| Completed | Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer NCT03093870 | ASLAN Pharmaceuticals | Phase 2 / Phase 3 |
| Unknown | Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System NCT03185988 | Shen Lin | Phase 2 |
| Completed | Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma NCT03079427 | Asan Medical Center | Phase 2 |
| Unknown | Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs NCT03311789 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Unknown | Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers NCT03144856 | Sun Yat-sen University | Phase 2 |
| Unknown | Observational Study on Patients With Hepatobiliary Tumors NCT04637048 | Gang Chen, MD | — |
| Terminated | Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers NCT03291899 | King Faisal Specialist Hospital & Research Center | Phase 2 |
| Completed | Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma NCT02966821 | Hutchison Medipharma Limited | Phase 2 |
| Terminated | Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC NCT02992340 | ASLAN Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers NCT02829918 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Programs To Support You During Chemotherapy NCT02489422 | Wake Forest University Health Sciences | N/A |
| Active Not Recruiting | A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer NCT02711553 | Eli Lilly and Company | Phase 2 |
| Completed | MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer NCT02773459 | Seoul National University Hospital | Phase 1 / Phase 2 |
| Completed | The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarc NCT03830606 | Aiping Zhou | Phase 2 |
| Completed | ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract NCT02351765 | The Christie NHS Foundation Trust | Phase 1 |
| Completed | A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combi NCT02586987 | AstraZeneca | Phase 1 |
| Withdrawn | Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers NCT02720601 | New Mexico Cancer Research Alliance | Phase 2 |
| Completed | Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combinatio NCT02579616 | Eisai Co., Ltd. | Phase 2 |
| Completed | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitio NCT02443324 | Eli Lilly and Company | Phase 1 |
| Completed | Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcin NCT02346032 | Samsung Medical Center | Phase 2 |
| Unknown | XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy NCT02350686 | Samsung Medical Center | Phase 2 |
| Completed | Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer NCT02433639 | Seoul National University Hospital | Phase 2 |
| Recruiting | Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer NCT05184400 | Herlev and Gentofte Hospital | — |
| Completed | Early Palliative Care on Quality of Life of Advanced Cancer Patients NCT02988635 | Azienda Ospedaliero-Universitaria di Parma | Phase 3 |
| Completed | GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer NCT02182778 | Kansai Hepatobiliary Oncology Group | Phase 3 |
| Active Not Recruiting | Extracellular RNA Markers of Liver Disease and Cancer NCT02908048 | Mayo Clinic | — |
| Completed | Covered Versus Uncovered Biliary Stents for Biliary Malignancies NCT02102984 | Nuovo Ospedale Civile S.Agostino Estense | N/A |
| Unknown | Multibending vs Conventional Endoscope for Direct Peroral Cholangioscopy NCT02189421 | Soonchunhyang University Hospital | N/A |
| Completed | Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cance NCT01926236 | The Christie NHS Foundation Trust | Phase 3 |
| Completed | X-MAS Biliary Study With Covered Biliary Stent NCT01899976 | Medinol Ltd. | N/A |
| Unknown | A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis NCT01821248 | Kansai Hepatobiliary Oncology Group | Phase 2 |
| Completed | Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer NCT01917617 | Kansai Hepatobiliary Oncology Group | Phase 2 |
| Completed | Vessel Resection and Reconstruction of Biliary Tract Cancers NCT01861483 | Kansai Hepatobiliary Oncology Group | — |
| Completed | Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer NCT01815307 | Kansai Hepatobiliary Oncology Group | Phase 2 |
| Completed | Parenteral Nutrition in Patients With Biliopancreatic Mass Lesions NCT02670265 | University Medicine Greifswald | N/A |
| Completed | A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major He NCT01713387 | Kansai Hepatobiliary Oncology Group | Phase 1 |
| Completed | Surgical Outcomes Database For Faculty of Hepatopancreatic Biliary Surgery NCT01657383 | Wake Forest University Health Sciences | — |
| Completed | Effect of Early Management on PAin and DEpression in Patients With PancreatoBiliary Cancer, EPADE-PB NCT01589328 | National Cancer Center, Korea | N/A |
| Completed | Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas NCT01572324 | Peking University | Phase 2 |
| Terminated | Endoscopic Therapy of Malignant Bile Duct Strictures NCT01543607 | Massachusetts General Hospital | N/A |
| Completed | Surgery Plus Celiac Nerve Block for Long-term Pancreatic Cancer Pain Control NCT02002806 | Indiana University | N/A |
| Completed | Second Line Therapy in Advanced Biliary Tract Cancer NCT01530503 | IRCCS San Raffaele | Phase 2 |
| Unknown | Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer NCT01494363 | Soon Chun Hyang University | Phase 2 |
| Completed | Comparison Between Winged Versus Traditional Plastic Stents for Biliary Drainage NCT06960733 | University of Leipzig | N/A |
| Completed | A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major He NCT01297998 | Kansai Hepatobiliary Oncology Group | Phase 1 |
| Completed | Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer NCT01291615 | Kansai Hepatobiliary Oncology Group | Phase 1 |
| Completed | Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer NCT01308840 | University of Rochester | Phase 2 |
| Completed | Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer NCT01284413 | Kansai Hepatobiliary Oncology Group | Phase 1 / Phase 2 |
| Unknown | Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer NCT01234051 | Korean South West Oncology Group | Phase 2 |
| Completed | Case Series Study of Biliary Tract Cancer Patients in Japan NCT01294085 | Kansai Hepatobiliary Oncology Group | — |
| Unknown | Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma) NCT01180153 | Peking University Cancer Hospital & Institute | Phase 2 |
| Unknown | SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer NCT01811277 | Peking University | Phase 2 |
| Completed | Endoluminal Radiofrequency Ablation for the Treatment of Malignant Biliary Stenosis NCT04801719 | Brno University Hospital | N/A |
| Terminated | A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract C NCT00955721 | University of Miami | Phase 1 / Phase 2 |
| Terminated | A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma NCT00881504 | Georgetown University | Phase 2 |
| Completed | Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer NCT00753675 | Genzyme, a Sanofi Company | Phase 2 |
| Completed | Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer NCT00832689 | Yonsei University | Phase 2 |
| Terminated | Phase II Study of Gemcitabine and TS-1 in Biliary Trat Cancer NCT01171755 | Samsung Medical Center | Phase 2 |
| Terminated | Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor) NCT00630890 | University of California, San Francisco | Phase 1 |
| Completed | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced C NCT00423254 | Mannkind Corporation | Phase 1 |
| Terminated | Storage of Bile From Routine Procedures to Study Risk Factors NCT00414843 | Indiana University School of Medicine | — |
| Completed | Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tra NCT00380588 | Eli Lilly and Company | Phase 2 |
| Completed | Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer NCT00361231 | Massachusetts General Hospital | Phase 2 |
| Completed | Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Ca NCT00142480 | Massachusetts General Hospital | Phase 2 |
| Terminated | XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors NCT00090025 | Helsinn Healthcare SA | Phase 3 |
| Completed | Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer NCT00123825 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | A Population-Based Case-Control Study of Biliary Tract Cancers in Shanghai, China NCT00339560 | National Cancer Institute (NCI) | — |